drugset / Trial / NCT00676299
A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.
Phase 1
Completed
19 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Janssen Pharmaceutica N.V., Belgium · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess JNJ-26483327 (a drug in development for cancer) for the safety of the drug in patients with advanced solid tumors that have not responded or are no longer responding to available therapies. The absorption, breakdown and elimination of the drug will also be studied.
Timeline
- Start
- 2006-08
- Primary completion
- —
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-26483327 | Small molecule | — | Oral |